|
| |
|
| |
|
| |
Welcome to PharmaShots Weekly
| | | Feb 16 Edition
|
|
| | PharmaShots Weekly is your Monday signal check: a fast, story-driven run-through of the deals, data, approvals, and platforms that actually shift the biopharma landscape.
|
|
|
|
|
| |
Eli Lilly to Acquire Orna Therapeutics for ~$2.4B Advancing Genetic Innovation
|
|
| | Iambic Therapeutics and Takeda Partner on AI Drug Discovery
|
|
| | Memo Therapeutics and CSL Advance Polyclonal IgG Collaboration
|
|
| | Insilico Medicine and China Medical System Expand AI Partnerships in CNS & Autoimmune
|
|
|
|
|
| |
Stay Curious.
| | | Stay informed!
|
|
| | Stay ahead with PharmaShots Weekly!
|
|
|
|
|
| |
|
| |
|
| |
Cover Story
|
| |
A Bold Bet on RNA: Madrigal Expands Its MASH Ambition with Global siRNA Deal
|
| |
Strategic Deals & Innovation Spotlight
|
| |
| • | Lilly’s $2.4B Orna Acquisition Advances Genetic Medicine
|
|
| • | Iambic–Takeda: AI Accelerates Oncology & GI Innovation
|
|
| • | Memo–CSL: Rewriting the Recombinant Polyclonal IgG Playbook
|
|
| • | Insilico–CMS: AI-Powered Expansion in CNS & Autoimmune
|
|
| • | Formycon–Lotus: Advancing Keytruda Biosimilar Strategy in APAC
|
|
| |
Clinical Pipeline Highlights
|
| |
| • | Primary Progressive Multiple Sclerosis (PPMS): Genentech’s Phase III FENtrepid Data
|
|
| • | Pediatric Diabetes: MannKind’s INHALE-1 Afrezza Trial
|
|
| • | Relapsing Multiple Sclerosis (RMS): Zenas’ Obexelimab Phase II Results
|
|
| • | MASLD & Severe Hypertriglyceridemia: OrsoBio’s TLC-2716 Phase IIa Data
|
|
| • | Severe Asthma: Upstream Bio’s VALIANT Phase II Results
|
|
| • | RAS-Mutant Solid Tumors: Adlai Nortye’s AN9025 Phase I U.S. Dosing
|
|
| • | Uncontrolled Asthma: AstraZeneca’s LOGOS & KALOS Phase III Outcomes
|
|
| • | IgA Nephropathy: Novartis’ P-III ALIGN Results
|
|
| |
Regulatory Roundup: From Review to Reality
|
| |
| • | Pfizer – Hympavzi (FDA Priority Review)
|
|
| • | GSK – Arexvy (NMPA Acceptance)
|
|
| • | Takeda – Oveporexton (FDA Priority Review)
|
|
| • | Krystal Biotech – KB707 (FDA RMAT Designation)
|
|
| • | Akeso – AK139 (NMPA Phase II Clearance)
|
|
| • | Merck – Keytruda & Keytruda Qlex Approval in Ovarian Cancer
|
|
| • | Ark Biopharmaceutical – AK3280 (FDA IND Clearance)
|
|
| • | Amgen – Uplizna (EC Approval in gMG)
|
|
| |
MedTech Regulatory Milestones
|
| |
| • | Median Technologies – eyonis LCS (FDA 510(k) Clearance)
|
|
| • | Novocure – Optune Pax (FDA Approval in Pancreatic Cancer)
|
|
| • | Encora Therapeutics – Encora X1 (FDA 510(k) Clearance)
|
|
| • | EYE PCR – fixOflex (CE Mark)
|
|
| |
Diagnostics & Biomarker Breakthroughs
|
| |
| • | Labcorp Launches Elecsys pTau-181 for Alzheimer’s Detection
|
|
| |
Veterinary Innovation
|
| |
| • | FDA Approves KBroVet for Canine Epilepsy
|
|
| |
|
| |
PharmaShots Awards 2026
|
| |
|
| |
Celebrating Innovation and Excellence Across the Global Pharma & Healthcare Industry
|
| |
We are thrilled to announce the PharmaShots Pharma Awards 2026, a premier virtual event dedicated to recognizing groundbreaking innovation, leadership, and excellence in the pharmaceutical and healthcare sectors worldwide.
|
| |
This prestigious initiative brings together industry leaders, innovators, and key decision-makers from around the globe, creating a unique platform to celebrate achievements and set new benchmarks for the industry.
|
| |
Why Partner with PharmaShots Pharma Awards?
|
| |
Our sponsorship opportunities allow partners to:
|
| |
| • | Showcase your brand in front of a highly engaged, global pharma audience.
|
|
| • | Position your organization as a leader in innovation and thought leadership.
|
|
| • | Gain exclusive networking access to decision-makers, innovators, and influencers shaping the future of healthcare.
|
|
| |
We are currently reaching out to potential sponsors to understand your engagement goals and preferred sponsorship avenues. Based on your input, our team will provide a customized sponsorship prospectus detailing benefits, opportunities, and recommended next steps.
|
| |
Date of Awards Announcement: May 1, 2026
|
| |
We invite organizations to join us in this landmark celebration. Your support will help us highlight excellence, inspire innovation, and strengthen connections across the global pharma ecosystem.
|
| |
Interested in exploring sponsorship opportunities?
Partner with us at the PharmaShots Pharma Awards, fill out your sponsorship form, here
|
| |
|
| |
|
| |
A Bold Bet on RNA: Madrigal Expands Its MASH Ambition with Global siRNA Deal
|
| |
|
| |
In a defining strategic move, Madrigal Pharmaceuticals has entered into an exclusive global license agreement with Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals for six preclinical siRNA programs targeting metabolic dysfunction-associated steatohepatitis (MASH).
|
| |
This is not just pipeline expansion — it is a calculated step to reinforce and extend leadership in one of biotech’s most competitive metabolic disease markets.
|
| |
Why This Move Matters
|
| |
siRNA Powerhouse: Six preclinical gene-silencing programs designed to precisely target key drivers of MASH progression.
|
| |
High-Stakes Economics: A $60M upfront payment, plus up to ~$4.4B in cumulative milestone payments and royalties — underscoring the scale and long-term vision behind the collaboration.
|
| |
Strategic Synergy: The siRNA portfolio complements Rezdiffra, Madrigal’s approved therapy, creating the potential for combination strategies that may enhance therapeutic outcomes.
|
| |
Development Momentum: IND-enabling studies for the initial assets are expected to begin in 2026, maintaining strong forward trajectory.
|
| |
The Bigger Strategic Picture
|
| |
Doubling Down on MASH: Madrigal strengthens its position in metabolic liver disease as competition and innovation accelerate across the field.
|
| |
Global Control, Global Vision: The agreement grants Madrigal exclusive worldwide rights to develop, manufacture, and commercialize all six candidates.
|
| |
RNA Meets Metabolic Expertise: By integrating advanced gene-silencing technology with established disease expertise, the company positions itself at the intersection of precision medicine and metabolic care.
|
| |
Pipeline Depth Beyond a Single Asset: This move evolves Madrigal from a single-product success into a broader metabolic franchise builder with multi-asset potential.
|
| |
As RNA therapeutics continue to gain momentum and MASH remains a high-unmet-need indication, this alliance reflects a larger strategic shift toward precision-driven metabolic innovation.
|
| |
For Madrigal, this is more than expansion, it is a decisive statement of long-term ambition in MASH.
|
| |
|
| |
| | Eli Lilly’s $2.4B Orna Deal Fuels Genetic Innovation
|
|
|
|
|
| |
Lilly’s Bold Bet on the Future: $2.4B Orna Acquisition Advances Genetic Innovation
|
| |
|
| |
In a transformative expansion of its genetic medicine capabilities, Eli Lilly has entered into a definitive agreement to acquire Orna Therapeutics, securing a differentiated platform designed to power long-term innovation in genetic medicine and in vivo cell engineering.
|
| |
Why It Matters
|
| |
| • | Mega Acquisition: Up to $2.4B cash deal with upfront + clinical milestones.
|
|
| • | Clinical Asset: ORN-252 in vivo CAR-T ready for B cell autoimmune diseases.
|
|
| • | Tech Leap: oRNA enables durable protein expression vs. traditional RNA/cell therapies.
|
|
| • | Strategic Bet: Validates in vivo engineering for immune-mediated breakthroughs.
|
|
| |
Strategic Focus
|
| |
| • | Genetic Expansion: Bolsters Lilly’s pipeline in programmable biology.
|
|
| • | Platform Power: Circular RNA tech for sustained, long-term expression.
|
|
| • | Autoimmune Push: Targets high-unmet B cell-driven diseases with in vivo CAR-T.
|
|
| • | Innovation Frontier: Merges RNA durability with cell engineering precision.
|
|
| |
This strategic move underscores Lilly’s commitment to shaping the next frontier of medicine—where programmable biology, durable genetic expression, and in vivo engineering converge to unlock breakthrough therapies for complex immune-mediated diseases.
|
| |
|
| |
| | Powering Progress Through Strategic Collaborations
|
|
|
|
|
| |
From Algorithms to Impact: Iambic and Takeda Fast-Track AI-Led Therapeutic Innovation
|
| |
|
| |
In a bold move to redefine small molecule innovation, Iambic Therapeutics has entered a multi-year technology and discovery collaboration with Takeda.
|
| |
The partnership will harness Iambic’s advanced AI drug discovery models to propel select high-priority small molecule programs across Takeda’s Oncology and Gastroenterology & Inflammation portfolios.
|
| |
Why It Matters
|
| |
| • | AI Powerhouse: Iambic’s models turbocharge Takeda’s oncology and GI small molecule programs.
|
|
| • | Mega Milestones: Over $1.7B in development/commercial payments plus royalties.
|
|
| • | Tech Breakthrough: NeuralPLexer predicts protein-ligand structures for faster, precise drug design.
|
|
| • | Momentum Builder: Highlights AI's rising role in high-unmet-need therapeutics.
|
|
| |
Strategic Focus
|
| |
| • | Portfolio Acceleration: Targets Takeda’s key oncology and gastroenterology priorities.
|
|
| • | Platform Validation: Showcases Iambic’s AI suite and wet labs for big-pharma scale.
|
|
| • | Innovation Fusion: Blends computational AI with experimental validation.
|
|
| • | High-Unmet Alignment: Delivers next-gen small molecules for oncology and GI inflammation.
|
|
| |
This strategic alliance signals growing momentum behind AI-powered drug discovery—where computational innovation meets therapeutic ambition to deliver transformative outcomes in areas of high unmet need.
|
| |
Rewriting the IgG Playbook: Memo and CSL Forge Transformational Alliance
|
| |
|
| |
In a significant step toward next-generation antibody therapeutics, Memo Therapeutics has entered into a strategic collaboration and exclusive option-to-license agreement with CSL for its recombinant polyclonal IgG technology.
|
| |
Why It Matters
|
| |
| • | Exclusive Option: CSL gains priority access to Memo’s polyclonal IgG candidates for immunology expansion.
|
|
| • | Massive Milestones: Up to CHF 265M (~$328M) plus single-digit royalties on sales.
|
|
| • | Tech Edge: Dropzylla platform revolutionizes cloning and expression of human antibody repertoires.
|
|
| • | Industry Shift: Validates recombinant polyclonals as a game-changer for complex diseases.
|
|
| |
Strategic Focus
|
| |
| • | Portfolio Boost: Strengthens CSL’s immunology lineup with innovative antibody tech.
|
|
| • | Platform Acceleration: Fuels Memo’s Dropzylla with R&D funding and big-pharma validation.
|
|
| • | Innovation Bet: Targets unmet needs in immunology via next-gen polyclonal therapies.
|
|
| • | Long-Term Value: Combines strategic investment with high-upside milestones and royalties.
|
|
| |
This partnership underscores growing industry confidence in recombinant polyclonal antibody platforms as a transformative approach to tackling complex diseases—combining innovation, strategic investment, and long-term value creation
|
| |
AI in Action: Insilico Medicine and CMS Accelerate Next-Gen CNS and Autoimmune Therapies
|
| |
In a strategic push to accelerate next-generation therapeutics, Insilico Medicine has entered into multiple AI-powered drug discovery collaborations with China Medical System (CMS), targeting programs across central nervous system (CNS) and autoimmune disease indications.
|
| |
Why It Matters
|
| |
| • | AI Precision: Pharma.AI powers target ID, small-molecule design, and optimization for CNS/autoimmune.
|
|
| • | Substantial Funding: Tens of millions HKD per program in R&D support.
|
|
| • | Co-Development: At least two programs blending AI discovery with CMS clinical expertise.
|
|
| • | Paradigm Shift: Elevates AI's role in tackling high-burden CNS and autoimmune diseases.
|
|
| |
Strategic Focus
|
| |
| • | Disease Expansion: Targets underserved CNS and autoimmune indications.
|
|
| • | Platform Leverage: Validates Insilico’s Pharma.AI for China/global markets.
|
|
| • | Regional Strength: CMS drives clinical/regulatory execution with local prowess.
|
|
| • | Innovation Synergy: Merges computational speed with proven development scale.
|
|
| |
This partnership reinforces the expanding role of AI in reshaping early-stage drug discovery—bridging algorithmic intelligence with clinical leadership to unlock new possibilities in high-burden disease areas.
|
| |
Advancing the APAC Frontier: Formycon and Lotus Accelerate Keytruda Biosimilar Strategy
|
| |
|
| |
Formycon & Lotus Advance APAC Strategy for Keytruda Biosimilar FYB206
Formycon and Lotus Pharmaceutical have announced the conclusion of their exclusive license agreement for FYB206, Formycon’s biosimilar candidate to Keytruda (pembrolizumab), across the Asia-Pacific (APAC) region.
|
| |
Why It Matters
|
| |
| • | APAC Exclusivity: Lotus gains rights to Keytruda biosimilar FYB206.
|
|
| • | Strong Economics: Upfront + milestones + gross profit share for Formycon.
|
|
| • | Timeline Clarity: Primary data Q1 2026, then tailored APAC submissions.
|
|
| • | Access Expansion: Boosts oncology biosimilar availability in high-growth region.
|
|
| |
Strategic Focus
|
| |
| • | Manufacturing Control: Formycon ensures global-quality supply chain.
|
|
| • | Regional Tailoring: Customized regulatory paths for APAC markets.
|
|
| • | Pipeline Momentum: Advances FYB206 toward commercialization.
|
|
| • | Biosimilar Growth: Targets pembrolizumab access in underserved areas.
|
|
| |
This collaboration marks a strategic step toward expanding access to high-quality oncology biosimilars in the APAC region—positioning FYB206 to potentially broaden patient access to pembrolizumab-based therapies in the years ahead.
|
| |
|
| |
| | Pipeline in Motion: Late-Stage Data Shaping the Future of Care
|
|
|
|
|
| |
Phase III FENtrepid Study by Genentech
|
| |
|
| |
Primary Progressive Multiple Sclerosis (PPMS)
Genentech reports positive Phase III FENtrepid topline results for fenebrutinib (QD, oral) vs. IV Ocrevus and matching placebos in 985 adults with PPMS.
|
| |
Key Details
|
| |
| • | Results: Achieved primary endpoint with 12% reduction in confirmed disability progression at 12 weeks (cCDP12); curves separated by week 24, consistent across subgroups/disease durations. 26% risk reduction on 9-Hole Peg Test (9HPT, upper limb function); 22% on EDSS + 9HPT composite (post-hoc).
|
|
| • | Next Steps: Regulatory submissions planned post-Phase III FENhance 1 readout in relapsing MS (H1 2026).
|
|
| • | Asset: Promising oral option for PPMS, highlighting impact on upper limb function and disability progression.
|
|
| |
These findings position fenebrutinib as a promising oral therapeutic candidate in PPMS, underscoring continued innovation in progressive MS.
|
| |
Pediatric Diabetes
MannKind announces first patient enrolled in Phase II INHALE-1 trial of Afrezza (inhaled insulin + basal insulin) in newly diagnosed pediatric type 1 diabetes patients.
|
| |
Key Details
|
| |
| • | Trial Design: 13-week study (optional 26-week extension); primary endpoint: % CGM users achieving ≥70% time-in-range (70–180 mg/dL) in final 14 days of Week 13.
|
|
| • | Next Steps: FDA accepted sBLA for Afrezza in pediatric T1D/T2D (Oct 2025); PDUFA date May 29, 2026.
|
|
| • | Asset: Early initiation of inhaled insulin to improve glycemic control in children post-diagnosis.
|
|
| |
These milestones underscore MannKind’s commitment to expanding innovative, patient-friendly insulin options for younger populations.
|
| |
Relapsing Multiple Sclerosis (RMS)
Zenas BioPharma reports robust Phase II results for obexelimab (250 mg SC weekly) vs. placebo, showing rapid disease control.
|
| |
Key Details
|
| |
| • | Results (Weeks 8/12): 95% reduction in cumulative new GdE T1 lesions (0.01 vs. 0.23 adjusted mean; 97.2% patients lesion-free); sustained to Week 24 (0.04 mean). 40% NfL reduction; stable EDSS (no disability progression).
|
|
| • | Next Steps: Data supports advancement in RMS portfolio.
|
|
| • | Asset: Rapid, durable lesion suppression with balanced B-cell levels.
|
|
| |
These findings highlight obexelimab’s potential to deliver rapid, durable suppression of inflammatory activity in RMS.
|
| |
MASLD & Severe Hypertriglyceridemia
|
| |
OrsoBio reports positive Phase IIa proof-of-concept topline results for TLC-2716 (6/12 mg QD oral) vs. placebo in 30 overweight patients.
|
| |
Key Details
|
| |
| • | Results: Met primary endpoint with significant reductions in fasting triglycerides/remnant cholesterol; MRI-PDFF-confirmed liver fat improvement. Pronounced TG drops in ≥500 mg/dL baseline subgroup; consistent cuts in total/non-HDL/VLDL cholesterol.
|
|
| • | Next Steps: Supports advancement in MASLD/metabolic conditions.
|
|
| • | Asset: Oral therapy targeting lipid dysregulation and liver fat.
|
|
| |
These findings position TLC-2716 as a promising candidate for cardiometabolic disease drivers.
|
| |
Severe Asthma
Upstream Bio reports positive Phase II VALIANT topline results for verekitug vs. placebo in 478 patients (~60 weeks treatment).
|
| |
Key Details
|
| |
| • | Results (Week 60): 56% AAER reduction (100 mg Q12W), 39% (400 mg Q24W); FEV1 gains of 122/139 mL; FeNO drops of 43.5%/44.9%. Significant Week 24 FEV1/FeNO improvements (100 mg Q12W, 400 mg Q24W).
|
|
| • | Next Steps: Advances to Phase III in asthma/CRSwNP post-regulatory interactions.
|
|
| • | Asset: Strong exacerbation reduction and lung function/inflammation improvements.
|
|
| |
These data mark an important step in addressing severe inflammatory airway diseases.
|
| |
RAS-Mutant Solid Tumors
|
| |
|
| |
Adlai Nortye doses first U.S. patient in ongoing Phase I trial of AN9025 (oral pan-RAS(ON) inhibitor) for advanced/metastatic solid tumors.
|
| |
Key Details
|
| |
| • | Trial Design: Multi-regional, open-label study (Adlai Nortye ex-Greater China; ASK Pharm in Greater China).
|
|
| • | Next Steps: Evaluates safety/antitumor activity across RAS mutations (e.g., pancreatic, lung, colorectal).
|
|
| • | Asset: Potent/durable preclinical activity vs. RAS-driven cancers.
|
|
| |
With U.S. dosing underway, AN9025 advances as a promising contender in RAS-mutant malignancies.
|
| |
Uncontrolled Asthma
|
| |
|
| |
AstraZeneca reports positive Phase III LOGOS/KALOS results for Breztri Aerosphere (BGF; triple ICS/LAMA/LABA) vs. PT009 and Symbicort pMDI; regulatory filings under global review.
|
| |
Key Details
|
| |
| • | Results (pooled, 24 weeks): 76 mL morning trough FEV1 gain; 90 mL FEV1 AUC0–3 improvement; reduced severe exacerbation rates (with/without recent history). Full data published in The Lancet Respiratory Medicine.
|
|
| • | Next Steps: Regulatory approvals pending across major regions.
|
|
| • | Asset: Single-inhaler triple therapy via Aerosphere pMDI targets multiple asthma pathways.
|
|
| |
These findings position Breztri as a compelling option for uncontrolled asthma patients.
|
| |
IgA Nephropathy (IgAN)
Novartis reports final Phase III ALIGN topline results for Vanrafia (atrasentan 0.75 mg QD oral) vs. placebo in 340 patients over 132 weeks.
|
| |
Key Details
|
| |
| • | Results: 2.39 mL/min/1.73m² eGFR improvement vs. placebo at Week 136; 2.59 mL/min/1.73m² at Week 132. Benefits sustained with background SGLT2i use.
|
|
| • | Next Steps: Pursues traditional approval in 2026 (accelerated approval secured U.S./China 2025 for proteinuria reduction).
|
|
| • | Asset: Durable kidney function protection beyond proteinuria control.
|
|
| |
With nearly three-year eGFR preservation, Vanrafia positions as a cornerstone IgAN therapy.
|
| |
|
| |
| | From Review to Reality: Regulatory Wins Drive Industry Progress
|
|
|
|
|
| |
Fast-Tracked Approvals, Faster Progress
|
| |
|
| |
This week’s regulatory landscape reflects continued acceleration across hematology, immunology, oncology, and rare diseases, highlighting strong pipeline advancement and global agency engagement.
|
| |
| • | Pfizer secured U.S. FDA Priority Review for Hympavzi, aimed at treating hemophilia A or B across two patient populations—potentially expanding innovation in bleeding disorder care.
|
|
| • | GSK received acceptance from China’s National Medical Products Administration (NMPA) for its regulatory submission of Arexvy, targeting prevention of lower respiratory tract disease in adults.
|
|
| • | Takeda gained U.S. FDA Priority Review for Oveporexton, a novel therapy for narcolepsy type 1 (NT1), underscoring continued innovation in sleep disorders.
|
|
| • | Krystal Biotech received FDA RMAT designation for KB707, advancing its potential role in treating advanced or metastatic non-small cell lung cancer (NSCLC).
|
|
| • | Akeso secured NMPA approval to initiate Phase II trials of AK139 across seven indications, signaling broad development ambitions.
|
|
| • | Merck received FDA approval for Keytruda and Keytruda Qlex, in combination with chemotherapy ± Avastin, for PD-L1–positive platinum-resistant ovarian carcinoma, expanding immunotherapy options in a difficult-to-treat setting.
|
|
| • | Ark Biopharmaceutical received FDA IND clearance to initiate a Phase II study of AK3280 in idiopathic pulmonary fibrosis (IPF).
|
|
| • | The European Commission approved Amgen’s Uplizna for generalized myasthenia gravis (gMG), broadening access to targeted biologic therapy across Europe.
|
|
| |
Together, these developments underscore sustained regulatory progress worldwide—bringing innovative therapies closer to patients across a wide spectrum of high-unmet-need diseases.
|
| |
|
| |
| | Advancing Precision: MedTech Regulatory Wins
|
|
|
|
|
| |
MedTech Regulatory Milestones: Advancing Precision Diagnostics & Therapeutic Innovation
|
| |
|
| |
This week’s MedTech landscape highlights meaningful regulatory progress across oncology diagnostics and neuromodulation technologies, bringing cutting-edge solutions closer to patients.
|
| |
| • | Median Technologies received U.S. FDA 510(k) clearance for eyonis LCS, an AI-powered solution designed to enhance lung cancer detection and diagnosis. The clearance reinforces growing confidence in AI-driven imaging tools to improve early detection and clinical decision-making.
|
|
| • | Novocure secured U.S. FDA approval for Optune Pax in combination with chemotherapy for pancreatic cancer—marking a significant expansion of Tumor Treating Fields (TTFields) technology into one of the most challenging solid tumors.
|
|
| • | Encora Therapeutics gained U.S. FDA 510(k) clearance for Encora X1, advancing a non-invasive therapeutic option for patients living with essential tremor.
|
|
| • | EYE PCR Secures CE Mark for fixOflex Endocapsular Device to Address Post-Cataract Complications
|
|
| |
Together, these approvals and clearances underscore the accelerating convergence of AI, bioelectronic medicine, and device-based oncology solutions, reshaping standards of care across high-burden diseases.
|
| |
|
| |
| | A Breakthrough in Alzheimer’s Detection: Labcorp Launches Elecsys pTau-181
|
|
|
|
|
| |
Labcorp Launches Elecsys pTau-181: Revolutionizing Alzheimer’s Blood Testing
|
| |
|
| |
Labcorp has rolled out the Elecsys pTau-181 test, a blood-based assay that measures phosphorylated Tau 181 protein to rule out Alzheimer’s-related amyloid pathology in adults aged 55+.
|
| |
Key Highlights:
|
| |
| • | 97.9% negative predictive value—a reliable tool for excluding Alzheimer’s in symptomatic patients.
|
|
| • | Less invasive alternative to amyloid PET scans or lumbar punctures, simplifying cognitive impairment diagnostics.
|
|
| |
This builds on Roche's Elecsys pTau217, FDA-cleared in 2025, which detects amyloid pathology via plasma Tau 217 levels.
|
| |
These blood-based biomarkers mark a shift to scalable, routine Alzheimer’s screening—potentially accelerating early intervention in neurology and biopharma pipelines.
|
| |
|
| |
| | A New Standard in Managing Canine Epilepsy
|
|
|
|
|
| |
KBroVet becomes the first FDA-approved drug for controlling seizures in dogs with idiopathic epilepsy
|
| |
|
| |
A major milestone in veterinary neurology— PRN Pharmacal has secured full approval from the U.S. Food and Drug Administration under NADA for KBroVet, indicated for the control of seizures associated with idiopathic epilepsy in dogs.
|
| |
KBroVet brings a thoughtfully designed, canine-specific formulation to a condition that requires long-term, consistent management. Key highlights include:
|
| |
| • | Renal excretion via glomerular filtration, offering an important option for dogs with liver concerns
|
|
| • | Once-daily dosing to simplify treatment routines for pet parents
|
|
| • | Flavored, chewable tablets developed specifically for dogs to enhance compliance
|
|
| • | With a half-life of ≥21 days, KBroVet helps maintain stable drug concentrations at steady state—reducing fluctuations even if a dose is missed. The therapy will be available in 60- and 180-count bottles and is set to transition to fully approved labeling around April–May 2026.
|
|
| |
This approval marks a meaningful advancement in evidence-based veterinary care—providing clinicians and pet owners with a fully FDA-approved, reliable option to help manage seizures and improve quality of life for dogs living with epilepsy.
|
| |
|
| |
| | ViVE 2026: Where Healthcare Leadership Meets Technology
|
|
|
|
|
| |
|
| |
ViVE 2026 is returning to Los Angeles, bringing together over 9,000 executives from across the healthcare ecosystem to explore the future of digital health and innovation. Co-created by HLTH Inc. and CHIME, the event is the premier forum where health system and payer leaders connect with innovators, investors, and solution providers driving measurable transformation in healthcare delivery.
|
| |
This is where CIOs, CTOs, CMIOs, and digital health executives come to accelerate strategy, evaluate what truly works, and build collaborations beyond the noise. In just a few days, ViVE delivers insights and connections that would otherwise take months to achieve.
|
| |
Attendees can expect thought-provoking sessions, hands-on demonstrations, and peer-to-peer networking with leaders shaping the next era of healthcare technology. From breakthrough solutions in telehealth, AI, and patient engagement to strategic discussions on digital transformation and operational efficiency, ViVE 2026 provides an immersive environment for actionable insights.
|
| |
Whether you’re looking to discover new technologies, foster partnerships, or gain executive-level insights, ViVE is the destination for those shaping what’s next in healthcare.
|
| |
Exclusive for the PharmaShots community:
|
| |
| • | Get $250 off ViVE General Attendee passes
|
|
| • | Use discount code: V26PHARMASHOTS
|
|
|
| |
Los Angeles | 2026 – don’t miss your chance to be part of the future of digital health.
|
| |
|
| |
| | That’s a Wrap for This Week
We will see you next week
|
|
|
|
|
| |
Boardroom to Bedside: The Forces Redefining Biopharma
|
| |
This week reflects a market leaning decisively into platform-driven growth and strategic consolidation. Eli Lilly’s ~$2.4B move for Orna Therapeutics underscores big pharma’s appetite for next-gen genetic medicine platforms, while AI-centric collaborations led by Iambic Therapeutics, Takeda, and Insilico Medicine signal that computational discovery is transitioning from experimental to strategic core. At the same time, partnerships involving Memo Therapeutics and CSL, alongside biosimilar expansion by Formycon, reflect a dual focus on innovation and lifecycle value capture. Coupled with late-stage data from leaders such as AstraZeneca and regulatory momentum from Pfizer, the broader signal is clear: capital is flowing toward differentiated platforms, scalable technologies, and assets capable of delivering both scientific edge and commercial durability.
|
| |
|
| |
Stay Ahead with PharmaShots Weekly
|
| |
Biopharma never slows down — breakthrough data drops overnight, billion-dollar deals reshape markets, and regulatory decisions redraw competitive landscapes in real time. Your intelligence stream shouldn’t lag behind.
|
| |
PharmaShots Weekly cuts through the noise and delivers what truly matters — pivotal pipeline updates, regulatory inflection points, competitive dynamics, clinical breakthroughs, and strategic transactions — distilled into a sharp, executive-ready brief you can absorb in minutes, not hours.
|
| |
Every Monday at 8:00 AM EST, you receive a clear, decision-focused snapshot of the forces shaping global pharma and biotech — curated for leaders who act on insight, not information overload.
|
| |
If this edition sparked ideas, make that momentum consistent. Subscribe to PharmaShots Weekly for intelligence that’s concise, credible, and crafted for decision-makers across R&D, Competitive Intelligence, Strategy, and Business Development.
|
| |
Know someone who values signal over clutter? Forward this edition.
Spotted an insight worth amplifying? Share it on LinkedIn and tag us — we champion sharp perspectives.
|
| |
The industry moves fast. Your intelligence should move faster.
|
| |
| | Questions?
Reach out to us [email protected] for any collaboration, comments or questions, and media inquiry.
|
|
|
|
|
| |
|
0 comments